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ABSTRACT 
Objective: The present study was designed to investigate the influence of sodium orthovanadate on the P85 (Regulatory Subunit of PI3-Kinase) and 
GSK-3 (Glycogen Synthase Kinase 3) expressions in skeletal muscle tissue to the decreasing of blood glucose levels of alloxan-induced diabetic mice.  
Methods: Mice were divided into 5 groups i. e. (1) naive group, (2) diabetic group and (3-5) orthovanadate-treated diabetic groups at the dose of 
16, 32 and 64 mg/kg BW respectively. Diabetic mice model was induced by intraperitoneal administration of alloxan monohydrate at the dose of 
200 mg/kgBW. Diabetic state was occurred on day 3 after alloxan injection and then started the treatment of sodium orthovanadate for 7 days. The 
muscular tissue was harvested on day 10 after treatment and was stained using routine histology staining, haematoxylin-eosin for morphological 
qualitative analysis and immunohistochemical approaches to observe the expressions of P85 and GSK-3 in skeletal muscle.  
Results: Diabetes condition was shown by the increasing of fasting blood glucose levels from 59.1 ± 11.2 mg/dL to 310.6 ± 107.2 mg/dL on day 3. 
Administration of sodium orthovanadate at the dose of 16, 32 and 64 mg/kg BW reduced the fasting blood glucose levels after 7 days treatment (p < 
0.001) at diabetic mice significantly. The results of histology staining showed that sodium orthovanadate improved a necrosis in skeletal muscle 
cells alloxan-induced diabetic mice. On immunohistochemical approaches, sodium orthovanadate might decreased the P85 expressions and 
increased the GSK-3 expressions in skeletal muscle cells alloxan-induced diabetic mice (p < 0.001). 
Conclusion: This study reveals that the administration of sodium orthovanadate on diabetic mice led to the attenuation of the PTPase activity. The 
inhibition cause a decreasing the expression of P85 and increasing of GSK-3 that cause the decreasing of blood glucose levels and an improvement of 
insulin target cells in the muscle cells.  
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INTRODUCTION 
Diabetes mellitus (DM) is the most common endocrine disorder in 
man, currently affecting over 170 million people world-wide and, 
potentially, over 365 million in the year 2030 [1]. Type 2 diabetes 
mellitus (T2DM) is the most common form of diabetes worldwide 
accounting for 90% of cases globally and affecting approximately 
4% of the world's adult population [2]. Besides β cell failure, the 
major pathophysiological event contributing to the development of 
T2DM is the resistance of target tissues to insulin [
Molecular mechanism that may potentially lead to insulin resistance 
is a disruption in the balance between the amounts of the 
phosphoinositide 3 kinase (PI3-kinase) subunits, consisting of a 
regulatory subunit P85, which is tightly associated with a catalytic 
subunit, P110. Normally, a pool of free P85 monomers exists in 
stoichiometric excess to the P110 catalytic subunit, with the P85-
P110 heterodimer being responsible for the PI3-kinase activity [1].  
1]. 
In insulin-resistant state, significantly increasing the expression of the 
free P85 monomers and bind to the phosphorylated IRS-1 proteins in 
insulin signaling pathway, blocking access to P85-P110 heterodimers 
and subsequently affecting the ability of insulin to stimulate the 
association of the P85-P110 heterodimer with IRS-1, thus reducing the 
PI3-kinase insulin signaling. On previous study, the excess in total P85 in 
skeletal muscle insulin resistance was entirely accounted for by an 
increase in the free P85α-specific isoform [3].  
Other mechanisms involved in the development of insulin resistance 
is a reduction of the cells capacity to synthesize and store glycogen 
by glycogen synthase kinase-3 (GSK-3) activation. GSK-3 was 
originally identified as a regulator of glycogen synthase (GS), a rate-
limiting enzyme that promotes glycogen deposition. In basal 
condition, stimulation of cells with insulin causes inactivation of 
GSK-3 through a PI 3-kinase-dependent mechanism. PI 3-kinase-
induced activation of PKB (also termed Akt) results in PKB 
phosphorylation of both GSK-3 isoforms (Ser9 of GSK-3β; Ser21 of 
GSK-3α), which inhibits GSK-3 activity.  
This leads to the dephosphorylation of substrates including GS, 
resulting in their functional activation and consequent increased 
glycogen synthesis. In insulin-resistant state, in the absence of 
insulin, GSK-3 was activated by tyrosine phospohorilation.  
The active GSK-3 will phosphorylate four serine residues in the 
C-terminal domain of GS and negatively regulate its activity, 
reduce the capacity of cells to synthesize and store glycogen [4, 
5]. 
Current antidiabetes therapies are generally safe and effective but 
have certain limitations, i. e. require the functional insulin 
receptor and non insulin oral antidiabetes therapies additionally 
require minimum endogenous levels of insulin.  
Therefore, insulin-mimetic compounds that act independently of 
insulin and the insulin receptor may thus represent a novel 
therapeutic strategy for severe insulin-resistant patients, T1DM, 
and T2DM [6]. 
Vanadium compounds act in an insulin-mimetic manner both in 
vitro and in vivo have been well established. Vanadium is an ultra 
trace element, widely distributed in the nature and its compounds 
would closely mimic the physiological action of insulin by initial 
entry into the portal system [7].  
In this regard and supporting a possible therapeutic use of 
vanadium, the present study aimed to investigate sodium ortho 
vanadate (SOV), the inorganic salt compound of vanadium, influence 
in the reduction of P85 expression and the elevation of GSK-3 
expression to the reduction of blood glucose levels of alloxan-
induced diabetic mice. Therefore, this mechanism will be the basis of 
new therapeutic strategies in patients with T2DM. 
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MATERIALS AND METHODS 
Animals and experimental groups 
A group of 25-40 male mice of Balb/C strain, weighing between 20-
30 g and 6-8 weeks of age, was obtained from Animal Laboratory at 
the Pharmacy Faculty, Airlangga University, Indonesia. Animals 
were maintained in the climatically controlled animal house facility 
of Animal Laboratory at the Pharmacy Faculty, for one week before 
the initiation of the experimentation.  
The animals were fed ad libitum with mice feed and tap water. All of 
mice were divided into five groups. Group 1 was non-diabetic 
control mice (n=5). Group 2 was diabetic-untreated control mice 
(n=5). Group 3 (n=5), Group 4 (n=5) and Group 5 (n=8) were 
diabetic-treated mice. The methodology of this experiment was 
performed after the approval by Airlangga University Animal Care 
and Use Committee (ACUC). 
Animal model of diabetes mellitus 
Diabetes was induced by a single intraperitoneal injection of alloxan 
monohydrate (Sigma Aldrich Inc.) at the dose of 200 mg/kgBW, was 
dissolved freshly in cold normal saline. Non-diabetic control mice 
received an injection of the vehicle. After 3 days, mice (n=23) with 
marked hyperglycemia (fasting blood glucose levels exceeding 140 
mg/dL) were selected and used for the study [8].  
Experimental protocol 
Group 1 and Group 2 were administered orally with aquadest
Determination of blood glucose levels 
. Group 
3 (n=5), Group 4 (n=5) and Group 5 (n=8) was forced-fed orally with 
sodium orthovanadate (Calbiochem Inc.) at the dose of 16, 32 and 64 
mg/kg BW/day for 7 days respectively. Fasting blood glucose levels 
were determined on day 0 (before the induction of diabetes), day 3 
(start of treatment), and day 10 (end of treatment). At the end of 
treatment (day 10), mice were anesthetised and skeletal muscle 
tissue were collected and fixed in 10% neutral buffered formalin for 
histochemistry and immunohistochemistry analysis.  
Blood samples were collected from the tail vein of 8-hours-fasted 
mice for determination of blood glucose levels using On-Call®
Analysis of skeletal muscle histology  
 Plus 
Blood Glucose Monitoring System. 
Skeletal muscle tissue were processed to any treatment of tissue 
necessary to impregnate them within a solid medium (paraffin wax) to 
facilitate the production of sections for microscopy, then were checked 
hystochemically by haematoxylin-eosin (HE) staining [9]. Observed 
using a light microscope with a magnification of 100 and 400x. 
Analysis of P85 and GSK-3 expressions  
Skeletal muscle tissue sections were checked 
immunohistochemically using PI3-kinase P85α antibody ((A01524-
100) GenScript Inc.) for P85 expressions and p-GSK-3β (Ser 9) 
antibody ((sc-11757) Santa Cruz Biotechnology Inc.) for GSK-3 
expressions, at 1:700 dilution. For the evaluation of P85 and GSK-3 
expressions, a modified semiquantitative IRS scale of Remmele was 
applied (Table 1). Semiquantitative IRS scale taking into account 
both percentage of positive cells (A) and intensity of the reaction 
colour (B), with the final score representing product of the two 
variables (A x B), and ranges from 0 to 12 pt [10]. 
Statistical analysis 
Analysis of the research data were processed with SPSS V.17.0 for 
windows with significance level p < 0.05. All data were expressed as 
mean ± Standard Deviation (SD). Differences of fasting blood glucose 
levels between day 0 and 3 on non-diabetic control group were analyzed 
with unpaired t-test. Differences of fasting blood glucose levels between 
day 0 and 3 on diabetic-untreated control
 
 group were analyzed with 
Mann-Whitney test. Differences of fasting blood glucose levels between 
groups on day 10 were analyzed with one-way ANOVA. Differences of 
P85 or GSK-3 expression between groups were analyzed with Kruskal-
Wallis test and followed by Mann-Whitney test. 
Table 1: Semiquantitative IRS scale 
A B 
0 pt – no cells with positive reaction 0 pt – no colour reaction 
1 pt – to 10% cells with positive reaction 1 pt – low intensity of colour reaction 
2 pt – 11-50% cells with positive reaction 2 pt – moderate intensity of colour reaction 
3 pt – 51-80% cells with positive reaction 3 pt – intense colour reaction 
4 pt – > 80% cells with positive reaction  
 
RESULTS 
Effect of alloxan monohydrate administration in naive mice 
Blood glucose levels of mice after the administration of alloxan 
monohydrate were summarized in table 2. In the naive mice group 
which only received vehicle injection intraperitoneally, no elevating 
in fasting blood glucose levels from day 0 to 3 significantly (p = 
0.274). While in the mice group that received alloxan monohydrate 
injection, there was an elevating of fasting blood glucose levels 
significantly from 59.1 ± 11.2 mg/dL on day 0 to 310.6 ± 107.2 
mg/dL on day 3 (p < 0.001).  
Histology of skeletal muscle cells after alloxan monohydrate 
administration 
The muscle cells in the sectional of skeletal muscle tissue of non-
diabetic mice looks solid, the shape and size of the cells were 
homogeneous, and had a nucleus at the cell edge (Fig. 1, sign ). 
While in the muscle cells of diabetic
Immunohistochemistry of P85 expressions in skeletal muscle cells  
 mice, the shape and size of the 
cells were not homogeneous, there was nucleus in the middle, 
swelling of the cell nucleus and aggregation of the cells that led to 
muscle cell necrosis (Fig. 1, sign ). 
The sectional of skeletal muscle tissue of non-diabetic mice, P85 was 
expressed in a sufficient quantities in the cytoplasm (Fig. 2, sign 
). While in the muscle cells of diabetic mice, P85 was more expressed 
than non-diabetic
Immunohistochemistry of GSK-3 expressions in skeletal muscle 
cells  
 mice, that described an excessive P85 (Fig. 2, sign 
). 
The sectional of skeletal muscle tissue of non-diabetic mice, GSK-3 
was expressed in a quite strongly in the cytoplasm (Fig. 3, sign ). 
While in the muscle cells of diabetic mice, GSK-3 was expressed 
weaker than non-diabetic
Effect of sodium orthovanadate (SOV) administration in DM 
mice 
 mice, that described a reduction of GSK-3 
phosphorilation (Fig. 3, sign ). 
Blood glucose levels of mice after the administration of sodium 
orthovanadate were summarized in table 3. Administration of 
sodium orthovanadate on diabetes condition for 7 days reduced 
fasting blood glucose levels on day 10. The higher dose of sodium 
orthovanadate, the greater reduction in fasting blood glucose levels.  
Histology of skeletal muscle cells after SOV administration 
After administration of sodium orthovanadate for 7 days, there was 
an improvement in skeletal muscle cells (Fig. 4). Cell nucleus in 
skeletal muscle cells was clearly visible, oval, located at the edge of 
the cell (Fig. 4, sign ), looks no further aggregation of cell 
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nucleus (Fig. 4, sign ) and inflammatory cells, the boundary of 
perimisium and endomisium seems clearly and closely so that the 
tissue looks more solid by muscle cells. The higher dose of sodium 
orthovanadate, the greater improvement in skeletal muscle cells. 
 
Table 2: Fasting blood glucose levels on day 0 and 3 
Group Total mice Blood glucose levels on day ± SD (mg/dL) Sig. 
0 3 
Naive 5 71.6 ± 10.2 78.4 ± 8.0 p = 0.274 
DM 23 59.1 ± 11.2 310.6 ± 107.2 p < 0.001 * 
Values are statistically significant at *
 
p < 0.05 vs day 0.  
 
Fig. 1: Appearance of skeletal muscle by HE staining. Naive state 
was shown by fig. A (magnification 100x) dan C (magnification 




Fig. 2: Expressions of P85 in skeletal muscle cells reacted with 
PI3-kinase P85α antibody with magnification 400x. Naive state 
was shown by fig. A. DM state was shown by fig. B. 
 
Immunohistochemistry of P85 and GSK-3 expressions in 
skeletal muscle cells  
The results of IRS scoring of the muscle cells that expressed the P85 
and GSK-3 were summarized in table 4. Administration of sodium 
orthovanadate for 7 days, reduced the excessive P85 expressions 
and increased GSK-3 expressions in skeletal muscle tissue. The 
higher dose of sodium orthovanadate, the greater reduction in P85 
expressions, was characterized by fewer brown color produced (Fig. 
5). The higher dose of sodium orthovanadate, the greater 
enhancement of GSK-3 expressions, was characterized by the 
growing strength of brown color produced (Fig. 6). 
 
 
Fig. 3: Expressions of GSK-3 in skeletal muscle cells reacted 
with p-GSK-3β antibody with magnification 400x. Naive state 
was shown by fig. A. DM state was shown by fig. B. 
 
 
Fig. 4: Appearance of skeletal muscle by HE staining with 
magnification 400x (A) DM. (B) DM+sodium orthovanadate 16 
mg/kgBW. (C) DM+sodium orthovanadate 32 mg/kgBW. (D) 
DM+sodium orthovanadate 64 mg/kgBW. 
 
Table 3: Fasting blood glucose levels on day 10 
Group Fasting blood glucose levels average on day 10 ± SD (mg/dL)  
Naive 64.6 ± 18.3* 
DM 406.4 ± 64.1 
DM+Sodium orthovanadate 16 mg/kgBW 303.0 ± 126.8
DM+Sodium orthovanadate 32 mg/kgBW 
* 
231.8 ± 57.1
DM+Sodium orthovanadate 64 mg/kgBW 
* 
75.6 ± 40.8* 
Values are statistically significant at *p < 0.05 vs DM group.  
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 Table 4: P85 and GSK-3 expressions 
Group Protein expressions average per field of-  
P85 GSK-3 
Naive 2.7 ± 1.4 6.2 ± 2.2* * 
DM 7.6 ± 1.6 3.2 ± 1.6 
DM+Sodium orthovanadate 16 mg/kgBW 6.4 ± 2.1 6.9 ± 2.2* 
DM+Sodium orthovanadate 32 mg/kgBW 
* 
4.5 ± 2.1 7.4 ± 2.3* 
DM+Sodium orthovanadate 64 mg/kgBW 
* 
3.9 ± 2.0 9.2 ± 2.4* * 
Values are statistically significant at *
 
p < 0.05 vs DM group.  
 
Fig. 5: Expressions of P85 in skeletal muscle cells reacted with 
PI3-kinase P85α antibody with magnification 400x (A) DM. (B) 
DM+sodium orthovanadate 16 mg/kgBW. (C) DM+sodium 




Fig. 6: Expressions of GSK-3 in skeletal muscle cells reacted 
with p-GSK-3β antibody with magnification 400x (A) DM. (B) 
DM+sodium orthovanadate 16 mg/kgBW. (C) DM+sodium 




The main finding of our study was that sodium orthovanadate reduced 
the excess of P85α expressions (Table 4; Fig. 5) and increased 
phosphorilation at serin-9 of GSK-3β expressions (Table 4; Fig. 6), would 
lead to the reduction of blood glucose levels (Table 3) and improved a 
necrosis in skeletal muscle cells alloxan-induced diabetic mice that given 
sodium orthovanadate treatment for 7 days (Fig. 4).  
Sodium orthovanadate adopts a trigonal bipyramidal structure that 
mimics the transition state of the phosphoryl transfer reaction, 
thereby acting as a competitive inhibitor of PTP-1B [11], allowing 
the phosphoester bond (which also forms an autophosphorylation) 
and thus the insulin signal transduction remain intact [12]. 
Inhibition of PTP-1B activity effectively raises the concentration of 
phosphorylated insulin receptor and IRS-1 [13], thereby allowing 
the tyrosine-phosphorylated IRS-1 to dock with the p85 regulatory 
subunit of phosphotidylinositol-3-kinase (PI3-kinase). This 
interaction unregulated the p110 catalytic subunit of PI3-kinase, 
which catalyzes the production of phosphoinositide moieties that 
subsequently activate 3-phosphoinositide-dependent kinases (PDK), 
including PDK1. One downstream target of PDK1 is the 
serine/threonine kinase Akt. Interestingly, one substrate for 
phosphorylation by Akt action is GSK-3. Akt phosphorylates specific 
serine residues on GSK-3 [14], inhibit GSK-3 via Ser 9/21 
phosphorylation, results in the dephosphorylation and activation of 
GS, leading to increased rates of glycogen synthesis [5], thereby 
improved a necrosis in skeletal muscle cells in diabetic state.  The 
activation of these steps up to and including PI3-kinase and Akt 
ultimately results in the translocation of a specific glucose 
transporter protein isoform (GLUT-4) to the membranes of the 
sarcolemma and the t-tubules, where glucose transport takes place 
via a facilitative diffusion process. The amount of GLUT-4 protein 
incorporated into the sarcolemmal membrane correlates closely 
with the degree of insulin-stimulated glucose transport [14], thereby 
reduced the elevation of blood glucose levels in diabetic state. 
Based on that finding, the reduction of P85 expressions and the 
elevation of GSK-3 expressions can be used for new therapeutic 
strategy to reduce the elevating blood glucose levels and to improve 
a necrosis that may happened in patients with T2DM. 
CONCLUSION 
Vanadium compounds improved metabolic disorders in models of 
type 2 diabetes mellitus. In type 2 diabetes mellitus, sodium 
orthovanadate treatment normalized hyperglycemia by reduced P85 
expressions and increased GSK-3 expressions in insulin signaling 
pathway. Hence, this compound is a potential candidate for oral 
therapy in diabetes as substitutes for insulin.  
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